We are live on ! Find out more
PRTK

Paratek Pharmaceuticals, Inc.

Delisted

PRTK was delisted on the 20th of September, 2023.

60 hedge funds and large institutions have $264M invested in Paratek Pharmaceuticals, Inc. in 2015 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 22 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 18

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

12% less funds holding

Funds holding: 6860 (-8)

24% less capital invested

Capital invested by funds: $346M → $264M (-$82.6M)

62% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 13

Holders
60
Holders Change
-8
Holders Change %
-11.76%
% of All Funds
1.68%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.11%
New
5
Increased
22
Reduced
18
Closed
13
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
TI
26
Turner Investments
Pennsylvania
$1M +$1.31M +52,720 New
Deutsche Bank
27
Deutsche Bank
Germany
$951K -$380K -15,243 -23%
TCIM
28
TIAA CREF Investment Management
New York
$928K +$212K +8,500 +21%
Geode Capital Management
29
Geode Capital Management
Massachusetts
$905K +$66K +2,649 +6%
USAA
30
United Services Automobile Association
Texas
$811K +$788K +31,620 +286%
BIM
31
BlackRock Investment Management
Delaware
$790K -$20.5K -821 -2%
California State Teachers Retirement System (CalSTRS)
32
California State Teachers Retirement System (CalSTRS)
California
$421K -$2.49K -100 -0.4%
Norges Bank
33
Norges Bank
Norway
$405K
TA
34
Teachers Advisors
New York
$335K
Charles Schwab
35
Charles Schwab
California
$331K
WMSA
36
Weiss Multi-Strategy Advisers
New York
$285K +$374K +15,000 New
New York State Common Retirement Fund
37
New York State Common Retirement Fund
New York
$222K +$120K +4,826 +70%
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$198K +$11.9K +477 +5%
AP
39
Appleton Partners
Massachusetts
$192K +$1.65K +66 +0.7%
MLICM
40
Metropolitan Life Insurance Company (MetLife)
New York
$175K
NFA
41
Nationwide Fund Advisors
Ohio
$148K -$2.57K -103 -1%
AIG
42
American International Group
New York
$136K +$199 +8 +0.1%
BA
43
BlackRock Advisors
Delaware
$125K -$127K -5,101 -44%
SG Americas Securities
44
SG Americas Securities
New York
$108K +$141K +5,674 New
IWMPD
45
Integrated Wealth Management (Palm Desert)
California
$86K
Bank of America
46
Bank of America
North Carolina
$62K +$43.1K +1,729 +111%
Morgan Stanley
47
Morgan Stanley
New York
$59K -$1.05K -42 -1%
PAM
48
Panagora Asset Management
Massachusetts
$55K -$140K -5,613 -66%
Wells Fargo
49
Wells Fargo
California
$54K +$53.7K +2,153 +311%
BNP Paribas Financial Markets
50
BNP Paribas Financial Markets
France
$46K +$35K +1,404 +138%

PRTK Hedge Fund Activity: Q3 2015 in Review

60 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q3 2015, worth a combined $264M — down 24% from $346M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of PRTK and 5 opened new positions — a net loss of 8 holders — while 18 trimmed existing stakes and 22 added.

The largest buyer was Granahan Investment Management, adding an estimated $4.96M. The largest seller was NEA Management Company, cutting an estimated $1.22M.

  • 60 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q3 2015, down from 68 in Q2 2015.
  • Funds reported $264M of Paratek Pharmaceuticals, Inc. stock for Q3 2015, down 24% quarter-over-quarter.
  • 5 funds opened new Paratek Pharmaceuticals, Inc. positions in Q3 2015 and 13 closed out, a net change of -8 holders.
  • The largest Paratek Pharmaceuticals, Inc. buyer in Q3 2015 was Granahan Investment Management, an estimated $4.96M added.
  • The largest Paratek Pharmaceuticals, Inc. seller in Q3 2015 was NEA Management Company, an estimated $1.22M sold.

Based on aggregated 13F filings for Q3 2015.